LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! New weapons on the way! Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE. I tried a different approach for this podcast, with more […]
The OPTIMAL-e trial is a phase 2 pilot study testing adaptive, PSMA-PET–guided radioligand therapy (RLT) with 177Lu-DOTA-HYNIC-panPSMA (TLX597-Tx) in men with metastatic hormone-sensitive prostate cancer (mHSPC), on top of standard androgen deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI). Conducted at St Vincent’s Hospital in Sydney, it is single-arm, open-label, and nonrandomized, designed […]
Prostate cancer usually responds poorly to immunotherapy because the tumor hides from the immune system, earning the label of an “immune‑cold” cancer. A new RNA‑targeted CRISPR technology developed at Duke University School of Medicine and collaborating institutions re‑exposes these tumors to immune attack in mice by restoring a key protein complex on cancer cells that […]
SHY-ONC6 is now entering a Phase 1 first-in-human clinical study in patients with advanced or metastatic solid tumors. The trial is open-label and multicenter, and its main goals are to assess safety, tolerability, pharmacokinetics, and early signs of anti-tumor activity in people whose disease has progressed on standard therapy or who cannot tolerate it. SHY-ONC6 […]
A new preclinical study shows that radioligand therapy (RLT) can directly enhance CAR‑T cell efficacy in metastatic castration-resistant prostate cancer (mCRPC), addressing two major barriers: antigen heterogeneity and an immunosuppressive tumor microenvironment (TME). Researchers combined 177Lu‑PSMA‑617 (Pluvicto) with PSCA-targeted CAR‑T cells in sequence (RLT → cyclophosphamide → CAR‑T). Compared to either treatment alone, the combination […]
Himalayas‑1 is a newly initiated global Phase 3 registrational trial testing rinzimetostat (ORIC-944) in combination with darolutamide in men with metastatic castration‑resistant prostate cancer (mCRPC) who have previously been treated with abiraterone. The trial is designed as a pivotal study intended to support approval if the results are positive, with about 600 patients planned across […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! A new week brings another batch of research, even if the pace is still slow. Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE. I […]
A recent study published in Small presents a novel way to treat bone metastases by combining nanotechnology, ultrasound, and immune activation into a single strategy. While the science behind it is complex, the concept is simple: create tiny particles that travel to bone tumors and, when activated by ultrasound, generate a highly localized anti-cancer effect. […]
Umeå University reports a novel fully human monoclonal antibody that blocks oncogenic signaling through the TGF‑β receptor I (TβRI), producing striking inhibition of both tumor growth and metastatic spread in aggressive prostate cancer models, according to a study published in Signal Transduction and Targeted Therapy. The antibody is composed entirely of human proteins, reducing immunogenicity […]
AO-252, a first-in-class TACC3 inhibitor, continues to show early clinical promise in advanced solid tumours, with recent updates highlighting both improved efficacy through optimized dosing and a new formulation designed to enhance drug exposure. Interim data from an ongoing Phase 1/2 trial demonstrated a clear dosing-dependent effect. Transitioning from once-daily (QD) to twice-daily (BID) administration […]